Adverts

Open Access Articles- Top Results for Lemborexant

Lemborexant

</th></tr>
Lemborexant
Systematic (IUPAC) name
(1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide
Clinical data
Identifiers
1369764-02-2
None
PubChem CID 56944144
ChemSpider 34500836
Chemical data
Formula C22H20F2N4O2
410.417 g/mol

Lemborexant (INN) (code name E-2006) is a dual antagonist of the orexin OX1 and OX2 receptors which is under development by Eisai for the treatment of insomnia.[1] [2][3] As of December 2014, it is in phase II clinical trials.[4]

See also

References

  1. ^ Christopher, John A (2014). "Small-molecule antagonists of the orexin receptors". Pharmaceutical Patent Analyst 3 (6): 625–638. ISSN 2046-8954. doi:10.4155/ppa.14.46. 
  2. ^ Cristoph Boss, Catherine Ross (2015). "Recent Trends in Orexin Research – 2010 to 2015". ScienceDirect. doi:10.1016/j.bmcl.2015.05.012. 
  3. ^ Boss, Christoph (2014). "Orexin receptor antagonists – a patent review (2010 to August 2014)". Expert Opinion on Therapeutic Patents 24 (12): 1367–1381. ISSN 1354-3776. doi:10.1517/13543776.2014.978859. 
  4. ^ AdisInsight. "Lemborexant". Springer. Retrieved 2015-05-23. 

External links



Lua error in package.lua at line 80: module 'Module:Buffer' not found.